Statistics (since 2007)

Status: Wednesday, 16. September 2026

15091 completed cases

Male patients 7098 47%
Female patients 7993 53%
Children and youths 3686 24%
Adults 11405 76%

completed cases per country:

Germany 11135 74%
Austria 1267 8%
Switzerland 2689 18%

3014 completed cases

Male patients 1619 54%
Female patients 1395 46%
Children and youths 1239 41%
Adults 1775 59%

3915 completed cases

Male patients 2180 56%
Female patients 1735 44%
Children and youths 1536 39%
Adults 2379 61%

completed cases per country:

Brazil 272 7%
Bulgaria 256 7%
Greece 410 10%
Ireland 252 6%
Italy 1036 26%
Poland 659 17%
Spain 732 19%
Romania 85 2%
Netherlands 92 2%
Croatia 36 1%

347 completed cases

Male patients 189 54%
Female patients 158 46%
Children and youths 305 88%
Adults 42 12%

Welcome

The Anaphylaxis Registry (NORA - Network for Online-Registration of Anaphylaxis) aims to collect data on severe allergic reactions. Since data collection began in 2007 across German-speaking countries, anaphylactic reactions have been continuously documented. Since 2011, NORA has been open internationally; since then, an average of around 1,300 cases per year have been recorded.
Overall, the most common triggers include insect venoms, foods, and medications—though their distribution differs between children (mainly foods) and adults (mainly insect venoms).
Anaphylaxis is a severe allergic reaction that can progress rapidly and may be fatal. An increase in anaphylactic reactions has been reported worldwide. Because anaphylactic reactions are not subject to mandatory reporting, there is no comprehensive official statistic on their frequency, course, and outcomes. In addition, modern life continually exposes people to new and sometimes unknown substances and environmental factors. Exotic foods, for example fruits, are imported from all over the world and consumed locally.
Within this project we aim to obtain information on triggers, cofactors, and treatment of patients who experienced a severe allergic reaction. Such data  will help to improve the knowledge and treatment modalities of affected patients.